Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Date of authorisation: 14/01/2016, Revision: 7, Status: Authorised
Evidence Dossier: Spectrila (asparaginase) for Acute Lymphoblastic Leukaemia What is established Spectrila is a medicinal product authorized by the European Commission for use in the European Union since January 14, 2016. It contains asparaginase as its active substance and is used as part of combination chemotherapy to treat acute lymphoblastic leukaemia (ALL)…
Terms of reference for the European Sales and Use of Antimicrobials for veterinary medicine (ESUAvet) network
Health & Science Evidence Dossier: European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) Network What is established The European Medicines Agency (EMA) has established the ESUAvet network to monitor the sales and use of antimicrobials in veterinary medicine across Europe. This initiative aligns with ongoing efforts to combat antimicrobial resistance…
European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) annual surveillance reports
Privacy & Data: European Surveillance of Antimicrobials in Veterinary Medicine What is established The European Medicines Agency (EMA) manages a comprehensive surveillance initiative called ESUAvet (European Sales and Use of Antimicrobials for Veterinary Medicine). It collects, analyses, and publishes annual data concerning the sales and use of antimicrobial medicinal products in animals…
Lebanon: Amend Media Law to Protect Free Expression
What is established On August 11, 2026, Lebanon’s parliament adopted a new media law after 16 years of deliberation. The law introduced important changes aimed at protecting freedom of expression, particularly in the context of online and media-related communication. Key provisions include: Ending pretrial detention for crimes related to free expression committed…
Saudi Arabia: Man Executed for Childhood Offenses
Human Rights Watch Report on Saudi Arabia’s Execution of Men for Alleged Childhood Offenses This evidence dossier reviews key information from a report published by Human Rights Watch on October 19, 2026, concerning recent executions and death sentences in Saudi Arabia involving men convicted of crimes allegedly committed as minors. The dossier…
Kazakh President’s Grandnephew Donates Sport University to State Following Investigative Report
Kazakh President’s Grandnephew Donates Sport University to State Following Investigative Report This dossier examines reporting by Radio Azattyq and the Organized Crime and Corruption Reporting Project (OCCRP) on a recent development in Kazakhstan’s education sector involving Nurassyl Medeu, the grandnephew of Kazakh President Kassym-Jomart Tokayev. The matter concerns the transfer of ownership…
Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Human Medicines European Public Assessment Report (EPAR): Foundayo (Orforglipron) – Status: Opinion What is Established On 15 October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the marketing authorization of a new medicine named Foundayo. The active ingredient of Foundayo is…
Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion
New Medicine Yuviwel for Achondroplasia: An Evidence Dossier What is established Yuviwel is a newly developed medicine containing the active substance navepegritide, a prodrug form of C-type natriuretic peptide (CNP). It is intended for the treatment of achondroplasia in children aged two years and older whose growth plates (epiphyses) have not yet…
Human medicines European public assessment report (EPAR): Iressa, gefitinib, Date of authorisation: 24/06/2009, Revision: 16, Status: Authorised
What is established Iressa is a medicine whose active ingredient is gefitinib, primarily used to treat adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that harbors activating mutations in the epidermal growth factor receptor (EGFR) gene. It is administered orally, typically one 250 mg tablet once daily, and can be…
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised
What is established Vizimpro (active substance: dacomitinib) is a medicine approved in the European Union for the treatment of adults with advanced or metastatic non-small cell lung cancer (NSCLC) who have specific mutations in the epidermal growth factor receptor (EGFR) gene. It is classified as a tyrosine kinase inhibitor (TKI) that blocks…